Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AXGN Stock Forecast 2026-2027
$38.72
Current Price
$2.06B
Market Cap
Buy 9
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to AXGN Price Targets
+42.0%
To High Target of $55.00
+29.1%
To Median Target of $50.00
+24.0%
To Low Target of $48.00
AXGN Price Momentum
-4.6%
1 Week Change
-13.1%
1 Month Change
+232.9%
1 Year Change
+18.3%
Year-to-Date Change
-17.5%
From 52W High of $46.95
+244.2%
From 52W Low of $11.25
📊 TOP ANALYST CALLS
Did AXGN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if AxoGen is one of their latest high-conviction picks.
Latest AXGN Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, AXGN has a bullish consensus with a median price target of $50.00 (ranging from $48.00 to $55.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $38.72, the median forecast implies a 29.1% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Larry Biegelsen at Wells Fargo, suggesting a 24.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AXGN Analyst Ratings
9
Buy
0
Hold
0
Sell
AXGN Price Target Range
Low
$48.00
Average
$50.00
High
$55.00
Current: $38.72
Latest AXGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AXGN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 29, 2026 | Canaccord Genuity | Caitlin Roberts | Buy | Maintains | $50.00 |
| Apr 29, 2026 | Citizens | David Turkaly | Market Outperform | Maintains | $50.00 |
| Apr 29, 2026 | Wells Fargo | Larry Biegelsen | Overweight | Maintains | $48.00 |
| Apr 29, 2026 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $50.00 |
| Apr 23, 2026 | Lake Street | Frank Takkinen | Buy | Maintains | $50.00 |
| Mar 30, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Feb 24, 2026 | Citizens | Market Outperform | Maintains | $N/A | |
| Feb 19, 2026 | Wells Fargo | Overweight | Initiates | $N/A | |
| Dec 5, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Dec 5, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Dec 4, 2025 | Jefferies | Buy | Maintains | $N/A | |
| Dec 4, 2025 | Lake Street | Buy | Maintains | $N/A | |
| Dec 1, 2025 | Mizuho | Outperform | Initiates | $N/A | |
| Oct 30, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Oct 30, 2025 | Raymond James | Outperform | Maintains | $N/A | |
| Oct 30, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Oct 30, 2025 | Citizens | Market Outperform | Maintains | $N/A | |
| Sep 30, 2025 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| May 13, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Mar 17, 2025 | Lake Street | Buy | Initiates | $N/A |
Axogen Inc. (AXGN) Competitors
The following stocks are similar to AxoGen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Axogen Inc. (AXGN) Financial Data
Axogen Inc. has a market capitalization of $2.06B with a P/E ratio of -113.9x. The company generates $238.10M in trailing twelve-month revenue with a -13.2% profit margin.
Revenue growth is +26.6% quarter-over-quarter, while maintaining an operating margin of -4.6% and return on equity of -18.0%.
Valuation Metrics
Market Cap
$2.06B
Enterprise Value
$2.02B
P/E Ratio
-113.9x
PEG Ratio
-0.3x
Price/Sales
8.8x
Growth & Margins
Revenue Growth (YoY)
+26.6%
Gross Margin
+75.2%
Operating Margin
-4.6%
Net Margin
-13.2%
EPS Growth
+26.6%
Financial Health
Cash/Price Ratio
+4.9%
Current Ratio
7.1x
Debt/Equity
8.4x
ROE
-18.0%
ROA
-2.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Axogen Inc. (AXGN) Business Model
About Axogen Inc.
What They Do
Develops surgical solutions for nerve regeneration.
Business Model
The company generates revenue by marketing and selling innovative surgical products designed for peripheral nerve repair. Its flagship products include the Avance Nerve Graft and various AxoGuard offerings, which cater to a range of healthcare providers, including surgeons specializing in hand, reconstructive, and oral surgery. By providing advanced biologically active technologies, Axogen positions itself as a leader in the niche market of nerve repair solutions.
Additional Information
Axogen Inc. operates in multiple international markets, focusing on restoring nerve function and improving patient quality of life. The company is headquartered in Alachua, Florida, and aims to establish its products as the standard of care in nerve repair surgery.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
622
CEO
Mr. Michael D. Dale
Country
United States
IPO Year
1990
Website
www.axogeninc.comAxogen Inc. (AXGN) Latest News & Analysis
Latest News
Quick Summary
Axogen, Inc. (Nasdaq: AXGN) will release its Q2 2026 financial results on July 29, 2026, followed by a conference call at 8:00 a.m. ET for investors.
Why It Matters
Axogen's upcoming financial results and conference call could impact its stock price, reflecting its performance and future growth prospects in the medical technology sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
AxoGen stock is rated a buy by all 10 analysts following strong earnings and an increase in 2026 guidance.
Why It Matters
AxoGen's strong earnings and unanimous analyst bullishness indicate potential growth, making it an attractive investment opportunity with positive future projections.
Source: Investors Business Daily
Market Sentiment:
Positive
Quick Summary
AxoGen (NASDAQ: AXGN) focuses on growing the peripheral nerve repair market. Recent reimbursement wins may positively impact growth, though their effects are not yet quantified.
Why It Matters
AxoGen's focus on peripheral nerve repair growth and recent reimbursement wins signal potential revenue boosts, impacting stock performance and investor confidence.
Source: MarketBeat
Market Sentiment:
Positive
Axogen, Inc. (AXGN) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
2 months ago
Quick Summary
Axogen, Inc. (AXGN) presented at the Bank of America Global Healthcare Conference, sharing insights and updates relevant to investors.
Why It Matters
Axogen's presentation at a major healthcare conference may signal new developments or strategies, impacting investor confidence and stock performance in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
No relevant financial information or context provided in the news excerpt regarding Alachua and Tampa, Florida. Further details are needed for an investor summary.
Why It Matters
The locations may indicate regional economic developments or company expansions, potentially affecting local markets and investment opportunities in those areas.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Axogen, Inc. (AXGN) Q1 2026 Earnings Call Transcript
2 months ago
Quick Summary
Axogen, Inc. (AXGN) held its Q1 2026 earnings call, detailing financial performance and strategic updates. Further specifics were shared on revenue, expenses, and future outlook.
Why It Matters
Axogen's Q1 2026 earnings call provides insights into its financial performance and strategy, influencing investor sentiment and stock value based on growth potential and market outlook.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About AXGN Stock
What is Axogen Inc.'s (AXGN) stock forecast for 2027?
Based on our analysis of 7 Wall Street analysts, Axogen Inc. (AXGN) has a median price target of $50.00. The highest price target is $55.00 and the lowest is $48.00.
Is AXGN stock a good investment in 2027?
According to current analyst ratings, AXGN has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $38.72. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AXGN stock?
Wall Street analysts predict AXGN stock could reach $50.00 in the next 12 months. This represents a 29.1% increase from the current price of $38.72. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Axogen Inc.'s business model?
The company generates revenue by marketing and selling innovative surgical products designed for peripheral nerve repair. Its flagship products include the Avance Nerve Graft and various AxoGuard offerings, which cater to a range of healthcare providers, including surgeons specializing in hand, reconstructive, and oral surgery. By providing advanced biologically active technologies, Axogen positions itself as a leader in the niche market of nerve repair solutions.
What is the highest forecasted price for AXGN Axogen Inc.?
The highest price target for AXGN is $55.00 from at , which represents a 42.0% increase from the current price of $38.72.
What is the lowest forecasted price for AXGN Axogen Inc.?
The lowest price target for AXGN is $48.00 from Larry Biegelsen at Wells Fargo, which represents a 24.0% increase from the current price of $38.72.
What is the overall AXGN consensus from analysts for Axogen Inc.?
The overall analyst consensus for AXGN is bullish. Out of 7 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $50.00.
How accurate are AXGN stock price projections?
Stock price projections, including those for Axogen Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 2:10 AM UTC